LPA1R Antagonist
Diabetic Kidney Disease (CKD), NASH/MASH, Idiopathic Pulmonary Fibrosis
PreclinicalActive
Key Facts
Indication
Diabetic Kidney Disease (CKD), NASH/MASH, Idiopathic Pulmonary Fibrosis
Phase
Preclinical
Status
Active
Company
About Epigen Biosciences
Epigen Biosciences is a preclinical biotech firm leveraging a multi-target approach to develop novel therapeutics for fibrotic and neurodegenerative diseases with high unmet need. Its pipeline is built on three core platforms: an LPA1 receptor antagonist for fibrosis, sigma-1 receptor ligands for neurodegeneration, and a p70 S6 kinase inhibitor for Fragile X Syndrome. The company employs innovative research models, including cerebral organoids, and collaborates with academic institutions like UCSD to advance its programs toward clinical development.
View full company profile